<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857997</url>
  </required_header>
  <id_info>
    <org_study_id>TRAN MAU-THEM PHRCI 2017</org_study_id>
    <nct_id>NCT03857997</nct_id>
  </id_info>
  <brief_title>Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability</brief_title>
  <acronym>DI-WA</acronym>
  <official_title>Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intellectual disability (ID) is a clinically and genetically heterogeneous condition that&#xD;
      often results in a diagnostic odyssey.&#xD;
&#xD;
      The deployment of high throughput sequencing (HTS) and in particular exome sequencing (WES)&#xD;
      has made it possible to identify many genes responsible for ID. However, the WES does not&#xD;
      identify the cause of ID in about two-thirds of patients, due to, for example, the uneven&#xD;
      depth and coverage of all exons, or the location of variants in non-exonic areas. It has thus&#xD;
      been shown that genome sequencing (WGS), which is still rarely used because it is more&#xD;
      complex and costly, would be more efficient, with an expected diagnostic rate of around 60%.&#xD;
&#xD;
      In response to the massive contribution of HTS in the diagnosis of patients suffering from&#xD;
      rare diseases, France has launched the France Plan MÃ©decine Genomique 2025 (PFMG2025) to&#xD;
      deploy HTS platforms, which will be able to carry out WGS, WES and RNA sequencing (RNA-seq),&#xD;
      and pilot studies to define the modalities for prescribing these examinations. Two&#xD;
      cost-effectiveness evaluations of these technologies, in comparison with the current strategy&#xD;
      for diagnosis of ID, are currently underway or planned in the short term in France: 1) PRME&#xD;
      DISSEQ, comparing the large DI459 panel versus WES, 2) the DEFIDIAG pilot study of the&#xD;
      PFMG2025 comparing WGS, in trio versus solo, versus current strategy. However, there are no&#xD;
      studies examining the place of the RNA-seq in the ID diagnostic decision tree.&#xD;
&#xD;
      However, some pathogenic variations are likely to have an effect on transcription. WES/WGS&#xD;
      can detect them but are not able to affirm their pathogenicity because it focuses on genomic&#xD;
      DNA. Only the RNA-seq makes it possible to study the transcription of candidate genes on a&#xD;
      large scale, providing an additional level of evidence on both known genes in human pathology&#xD;
      (OMIM) and candidate genes.&#xD;
&#xD;
      The RNA-seq would increase the diagnostic rate from 10% to 35% in addition to the WGS in&#xD;
      negative patients with first-line approaches (including WES) and thus optimize management by&#xD;
      reducing diagnostic delays as part of a personalized care pathway.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>additional etiological diagnosis of intellectual disability</measure>
    <time_frame>At the time of analysis</time_frame>
    <description>Identification of additional etiological diagnosis of intellectual disability by the WGS-trio + RNA-seq vs WGS trio strategy.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Patients With Intellectual Disabilities Without an Obvious Clinical Diagnosis</condition>
  <condition>Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Patient blood sampling</intervention_name>
    <description>sequencing by WGS and RNA-seq</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Parents blood sampling</intervention_name>
    <description>sequencing by WGS</description>
    <arm_group_label>Parents</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient in consultation for intellectual disability&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  individuals with intellectual disabilities without an obvious clinical diagnosis,&#xD;
&#xD;
          -  idividuals with normal array CGH and previous negative genetic explorations (WES-solo&#xD;
             or WES-trio),&#xD;
&#xD;
          -  individuals whose sampling is possible in the index case and the 2 biological parents&#xD;
             in order to carry out a trio sequencing,&#xD;
&#xD;
          -  individuals having given their written consent (consent of the legal representative(s)&#xD;
             if the patient is a minor or incapacitated),&#xD;
&#xD;
          -  individuals whose biological parents have given their consent to be sampled,&#xD;
&#xD;
          -  individuals affiliated to or beneficiaries of the national health insurance system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding woman,&#xD;
&#xD;
          -  individuals for whom there is a diagnostic hypothesis considered highly probable and&#xD;
             for which a molecular test routinely available has a lower cost than the genome,&#xD;
&#xD;
          -  individual whose parents refuse to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

